P/E ratio for MariMed (MRMD)
P/E ratio as of April 2024 (TTM): 16.7
According to MariMed's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 16.7141. At the end of 2022 the company had a P/E ratio of 8.90.
P/E ratio history for MariMed from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 8.90 | -79.42% |
| 2021 | 43.3 | 39% |
| 2020 | 31.1 | -2069.18% |
| 2019 | -1.58 | -96.6% |
| 2018 | -46.4 | -59.63% |
| 2017 | -115 | 151.73% |
| 2016 | -45.7 | 1230.63% |
| 2015 | -3.43 | 683.05% |
| 2014 | -0.4384 | -85.35% |
| 2013 | -2.99 | 427.33% |
| 2012 | -0.5676 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.